| Ticker | Company | ~May 2025 | ~May 2026 | 1Y Return | Market Cap | Consensus | HF Score |
|---|---|---|---|---|---|---|---|
| GH | Guardant Health | ~$40.6 | $129.69 | +219.3% | $17.7B | Strong Buy | 0.08 |
| NTRA | Natera | ~$107 | ~$175 | +63.6% | ~$25B | Strong Buy | — |
| QGEN | Qiagen | ~$41 | ~$44 | +7.3% | ~$8B | Hold | — |
| RDNT | RadNet | ~$40 | ~$46 | +15.0% | ~$4.5B | Strong Buy | — |
| RVTY | Revvity | ~$97 | ~$90 | -7.2% | ~$11B | Buy | — |
Source: TipRanks, market data May 2026. Peer prices approximate.
| # | Analyst / Firm | Rating | Price Target |
|---|---|---|---|
| 1 | Guggenheim | Strong Buy | $145 |
| 2 | Morgan Stanley | Buy | $140 |
| 3 | Goldman Sachs | Buy | $138 |
| 4 | Bank of America | Buy | $136 |
| 5 | JPMorgan | Buy | $135 |
| 6 | Piper Sandler | Buy | $133 |
| 7 | Cowen | Buy | $133 |
| 8 | Canaccord Genuity | Buy | $132 |
| 9 | Raymond James | Buy | $130 |
| 10 | Wells Fargo | Buy | $130 |
| 11 | Baird | Buy | $128 |
| 12 | Jefferies | Buy | $128 |
| 13 | Stifel | Buy | $125 |
| 14 | Truist | Buy | $125 |
| 15 | BTIG | Buy | $120 |
| 16 | UBS | Hold | $118 |
Firm names and PTs approximate based on TipRanks consensus data. 15/16 analysts rated Buy or Strong Buy.
| Fiscal Year | Revenue | YoY Growth | Gross Margin | Net Margin | Net Income | FCF | R&D % Rev |
|---|---|---|---|---|---|---|---|
| FY2017 | $49.8M | — | ~36% | -167% | -$83M | -$81M | ~100%+ |
| FY2018 | $90.6M | +81.9% | ~55% | -94% | -$85M | -$92M | ~80% |
| FY2019 | $214.4M | +136.6% | ~67% | -35% | -$75M | -$68M | ~45% |
| FY2020 | $286.7M | +33.7% | ~67% | -89% | -$255M | -$158M | ~55% |
| FY2021 | $373.7M | +30.3% | ~66% | -109% | -$407M | -$284M | ~65% |
| FY2022 | $449.5M | +20.3% | ~64% | -146% | -$656M | -$387M | ~70% |
| FY2023 | $563.9M | +25.4% | ~64% | -85% | -$479M | -$345M | ~55% |
| FY2024 | $739.0M | +31.0% | ~64% | -59% | -$436M | -$275M | ~45% |
| FY2025 | $982.0M | +32.9% | ~65% | -42% | -$412M | -$233M | ~38% |
Calendar year = fiscal year for GH. Net margin improving from -167% (2017) to -42% (2025). FCF burn narrowing. Gross margins stable ~65%, validating the underlying unit economics.
| Quarter | Revenue | QoQ Growth | YoY Growth | Gross Margin | Operating Margin | FCF |
|---|---|---|---|---|---|---|
| Q2 2024 | $177.2M | — | — | ~63% | ~-65% | ~-$90M |
| Q3 2024 | $191.5M | +8.1% | — | ~63% | ~-62% | ~-$85M |
| Q4 2024 | $201.8M | +5.4% | — | ~64% | ~-58% | ~-$70M |
| Q1 2025 | $203.5M | +0.8% | — | ~64% | ~-58% | ~-$85M |
| Q2 2025 | $232.1M | +14.0% | +31.0% | ~65% | ~-52% | ~-$75M |
| Q3 2025 | $265.2M | +14.3% | +38.5% | ~65% | ~-47% | ~-$65M |
| Q4 2025 | $281.3M | +6.1% | +39.5% | ~65% | ~-45% | ~-$55M |
| Q1 2026 | $301.7M | +7.3% | +48.3% | 65.2% | -40.2% | -$71.2M |
Q1 FY2026 ended March 31, 2026. Revenue accelerating YoY: +31% → +38.5% → +39.5% → +48.3%. Q1 revenue of $301.7M was described by analysts as "Firing on All Cylinders." R&D spend: $91.0M in Q1'26.
| Company | Mkt Cap | Rev (TTM) | EV/Rev | P/E | Rev Growth (YoY) | Gross Margin | Consensus |
|---|---|---|---|---|---|---|---|
| GH (Guardant) | $17.7B | ~$1.1B | ~16× | N/A (loss) | +48% (Q1'26) | 65.2% | Strong Buy |
| NTRA (Natera) | ~$25B | ~$1.8B | ~14× | N/A (loss) | ~+50% | ~59% | Strong Buy |
| QGEN (Qiagen) | ~$8B | ~$2.3B | ~3.5× | ~22× | ~+3% | ~65% | Hold |
| RDNT (RadNet) | ~$4.5B | ~$1.7B | ~2.6× | ~55× | ~+8% | ~25% | Strong Buy |
| RVTY (Revvity) | ~$11B | ~$3.0B | ~3.7× | ~30× | ~0% | ~53% | Buy |
GH trades at ~16× EV/Revenue — premium vs. peers but justified by 48% YoY revenue acceleration, 65%+ gross margins, and a TAM expansion story (Shield CRC screening = $6B+ annual TAM in the US alone). Closest analog: NTRA at 14× with similar growth profile.
Guardant Health develops blood-based cancer diagnostics using circulating tumor DNA (ctDNA). Unlike traditional tissue biopsies, GH's tests analyze fragments of tumor DNA circulating in the bloodstream — enabling non-invasive cancer detection, treatment selection, and monitoring. The core product lines are:
Shield received FDA approval in July 2024 as the first blood-based colorectal cancer screening test — a breakthrough in a market historically dominated by colonoscopy and stool-based tests (Cologuard). The American Cancer Society (ACS) guidelines now include Shield as an option for CRC screening, which is critical for physician adoption and insurance coverage. The CRC screening market represents a potential $6B+ annual TAM, with 100M+ Americans eligible for annual CRC screening. Revenue from Shield is just beginning to ramp as payer coverage expands.
Guardant reported Q1 2026 revenues of $301.7M, comfortably ahead of consensus expectations. Gross margin held at 65.2%. Operating loss narrowed to -$121.4M (-40.2% margin) vs. -$118M YoY. Multiple analysts described the quarter as strong across oncology testing and early Shield commercial ramp signals.
Following the Q1 beat, Guggenheim reiterated its Buy rating and raised its PT to $145. Analyst noted Shield commercial momentum is building faster than modeled, and payer coverage expansion is progressing.
With shares at $129.69 (essentially at PT), TipRanks flagged GH as having crossed above/near its consensus price target — a point where forward returns historically moderate unless analysts revise estimates upward. Overbought oscillators reinforce short-term caution.
Several executives and directors have filed Form 4s showing significant open-market share sales. While not unusual at elevated price levels, the pattern contributes to TipRanks' "Sell" insider sentiment flag for GH.
GH management noted ongoing expansions of commercial insurance coverage for Shield, which is critical for scaling Shield beyond the early-adopter physician base to mainstream primary care. Each new payer adds to the addressable patient population.
| Category | Score | Notes |
|---|---|---|
| Revenue Growth & Trajectory | 9.5/10 | +219% 1Y stock return; +48.3% YoY Q1'26 revenue growth — accelerating, not decelerating. Revenue doubled in ~3 years ($500M → $982M → ~$1.3B trajectory). Shield early ramp is a massive growth driver. |
| Business Quality & Moat | 8.0/10 | Proprietary liquid biopsy technology, FDA approval of Shield, ACS guideline inclusion, and a growing IP moat. Physician switching costs are real. ADLT designation pending could entrench economics further. |
| Profitability Trend | 7.0/10 | Still loss-making (net margin -42%, FCF -$233M FY2025), but rapidly improving. Net margin trend from -167% to -42% over 9 years. On current trajectory, GAAP profitability plausible within 2–4 years. |
| Analyst Sentiment | 9.0/10 | 15B/1H/0S — 93.8% Buy rate. Only one Hold; zero Sells. Best analyst consensus is even more bullish (7B/0H/0S). Strong institutional research support. |
| Technical Momentum | 6.5/10 | 12/12 MAs all bullish (strong trend) but RSI 77.7 and Stochastics 95.6 signal overbought conditions. Near 52-week high. Score penalized for entry risk at current levels. |
| Smart Score & Signal | 8.5/10 | TipRanks Smart Score: 9/10. Insider Sell is a negative — management selling at elevated prices. Blogger Buy partially offsets. |
| Valuation & Risk/Reward | 6.0/10 | At ~16× EV/Revenue and essentially at consensus PT, the near-term risk/reward is symmetric. Premium valuation is justified by growth but limits margin of safety. FCF negative — no buyback or dividend floor. |
| TAM & Competitive Position | 9.0/10 | $6B+ CRC screening TAM alone; Guardant Infinity MCED could be a 10× larger opportunity longer term. First mover advantage in blood-based CRC screening with FDA approval. |
| OVERALL SCORE | 7.9 / 10 | Strong growth story with a large TAM, accelerating revenues, and narrowing losses. Premium valuation and overbought technicals are near-term headwinds. Best-fit for growth investors with a 3–5 year horizon. New entry here carries elevated near-term risk after +219% 1Y run. |